CD274 and head and neck squamous cell carcinoma: A Phase I immuno-radiotherapy with cetuximab and avelumab (Bavencio), a PD-L1 inhibitor, showed that cetuximab-RT plus avelumab is feasible in patients with advanced-stage HNSCC who are not good candidates for cisplatin treatment.